Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567580 · ClinicalTrials.gov registry record · Phase 3
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Radiation Therapy Oncology Group.
- Active
- Registry status
- Phase 3
- Development phase
- 1,792
- Enrollment target
- 20
- Study locations
NCT00567580: Active Phase 3 study of Prostate Cancer, sponsored by Radiation Therapy Oncology Group.
NCT00567580 is a Phase 3 study of Prostate Cancer that is active but no longer recruiting, run by Radiation Therapy Oncology Group. The registered enrollment target is 1,792 participants, above the 606-participant average among 735 other Prostate Cancer trials with a reported enrollment target (196% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00567580, a Phase 3 study of Prostate Cancer, is active but no longer recruiting, sponsored by Radiation Therapy Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,792 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, and luteinizing hormone-releasing hormone agonist, may lessen the amount of androgens made by the body. It is not yet known which regimen of radiation therapy with or without androgen-deprivation therapy is more effective for prostate cancer. PURPOSE: This randomized phase III trial is studying prostate radiation therapy to see how well it works compared with short-term androgen deprivation therapy given together with pelvic lymph node radiation therapy with or without prostate radiation therapy in treating patients with a rising PSA after surgery for prostate cancer.
Conditions Studied
Interventions
- DRUG LHRH agonist
- RADIATION PBRT
- RADIATION PLNRT
- DRUG AA
Study Locations (20)
California
- Auburn Radiation Oncology - Auburn
- Peninsula Medical Center - Burlingame
- Radiation Oncology Centers - Cameron Park - Cameron Park
- Mercy Cancer Center at Mercy San Juan Medical Center - Carmichael
- East Bay Radiation Oncology Center - Castro Valley
- Valley Medical Oncology Consultants - Castro Valley - Castro Valley
- Enloe Cancer Center at Enloe Medical Center - Chico
- Valley Medical Oncology - Fremont
- Washington Township Hospital - Fremont
- California Cancer Center - Woodward Park Office - Fresno
- Cancer Care Associates - Fresno
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Veterans Affairs Medical Center - Long Beach - Long Beach
- Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center - Los Angeles
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
Arizona
- Arizona Center for Cancer Care - Peoria - Peoria
- Arizona Oncology Services Foundation - Phoenix
- Arizona Oncology - Tucson - Tucson
Alabama
- UAB Comprehensive Cancer Center - Birmingham
Alaska
- Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital - Fairbanks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,792 participants |
| Start Date | 2008-02 |
| Phase | Phase 3 |
What the registry record for NCT00567580 still lists
NCT00567580 is an interventional study that assigns participants to a tested intervention. Its 1,792 participants enrollment target places it among the larger protocols in the corpus, above the 606-participant average among 735 other Prostate Cancer trials with a reported enrollment target (196% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which LHRH agonist is the first listed.
NCT00567580 names 20 study sites across 4 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00567580 about?
NCT00567580 is a clinical study titled "Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, and luteinizing hormone-releasing hormone agonist, may lessen the amount of androgens made by the body. It is not y...
What is the current status of trial NCT00567580?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,792 participants. The study started on 2008-02.
What conditions does trial NCT00567580 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00567580?
The interventions under investigation include: LHRH agonist (DRUG), PBRT (RADIATION), PLNRT (RADIATION), AA (DRUG).
Who is sponsoring clinical trial NCT00567580?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00567580 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00567580's enrollment target sits among peer trials
1,792 30th of 735 higher than 706 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05770570 · 1,785 participants · Phase 2
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia